The V-line request: what masseter toxin can and can't do to a jawline
Of all the treatments Korean aesthetics exported to the rest of the world, jaw slimming is probably the one that travelled furthest with the least explanation attached. Patients arrive with a saved photo and the word "V-line", and a fair number of them are asking for something botulinum toxin cannot give them.
That mismatch, more than technique, is what makes this treatment go wrong. So this is a piece about the consultation as much as the injection.
First question: what's actually making the face wide?
Stand behind the patient, put your fingers over the angle of the jaw, ask them to clench. Then relax. Then clench again.
Four things create width down there, and they respond to completely different treatments.
Masseter muscle. Bulges hard under your fingers on clench, softens on release. This is the one toxin treats, and treats well.
Subcutaneous and buccal fat. Doesn't change with clenching. Sits softer, often lower. Toxin does nothing here. This is where injectable lipolytics or surgical options come into the conversation.
Bone. A wide mandibular angle is a wide mandibular angle. No injection changes skeletal width, and a patient whose reference photo is of someone with a fundamentally different jaw shape needs to hear that in the consultation rather, than at week eight.
Submental fullness and poor cervicomental definition. Frequently read by the patient as "wide face" when it's actually a profile problem.
Most real faces are a mix. The useful consultation output isn't "yes we can do it", it's a proportion, roughly how much of what she dislikes is muscle, and therefore roughly how much of it toxin can address. Say the number out loud. "I think about half of this is muscle" sets a completely different expectation from silent nodding.
Two things make masseter hypertrophy more likely and both are worth asking aboutб bruxism, and habitual heavy chewing – gum, dried squid, ice, tough meat. Patients rarely volunteer this and it changes the longevity conversation.
The injection zone
The masseter is generous in size but the useful target is a defined box, and staying inside it is what separates a good result from a crooked smile.
Mark the anterior and posterior borders with the patient clenching. The posterior boundary is the mandibular ramus, the anterior border is more variable than diagrams suggest, which is why you palpate rather, than assume.
The upper limit is the line from the tragus to the oral commissure. Injecting above it drifts toward the zygomaticus and risorius territory, and that's the mechanism behind the asymmetric or "flattened" smile, that patients notice in photographs about ten days later. The lower limit sits roughly a centimetre above the inferior mandibular border, because product placed too low tends to migrate below the muscle without doing anything useful.
Inside that box, three to five points per side, needle perpendicular, deep – down to bone, then withdraw a fraction. Superficial placement is a common cause of the bulging complaint described below.
On dilution, this is a large muscle belly where even distribution matters more than pinpoint containment, so a more dilute preparation makes sense. We went through the concentration logic and the unit maths in the reconstitution guide, including the 200U vial trap, that catches busy clinics.
Dose, and why the second session is different
Published dose ranges for masseter work vary a lot, and the commonly cited figures sit somewhere around twenty to thirty units per side for a typical hypertrophic masseter, with heavier male muscles taking more. Take those as orientation, not as a protocol – follow your training and the specific product insert.
What's less often explained is the trajectory across sessions. The muscle atrophies with disuse, and that atrophy accumulates. A patient treated three or four times at appropriate intervals often needs less product per session by the second year, than she did at the start, and treating her at the original dose forever is both wasteful and, in some faces, unhelpful.
Intervals of roughly four to six months suit most patients. Treating much more frequently than the muscle's recovery curve doesn't accelerate anything.
The timeline patients aren't told
This is the single biggest source of complaints, and it's entirely preventable with one sentence at the consultation.
Filler patients see a result immediately. Masseter patients do not. The muscle has to stop working, then waste, and that takes time:
- Week 1–2: chewing may feel tired or slightly weak. No visible change. This is normal and worth warning about, because a patient who wasn't warned interprets it as something going wrong.
- Week 4: early softening of the angle, usually visible to the injector and not to the patient.
- Week 6–8: the change patients came for.
- Month 3: peak.
- Month 4–6: gradual return.
Tell them six to eight weeks. Photograph at baseline in standardised lighting from the front and from below, because this is a treatment where the mirror lies and the camera doesn't. Then bring the photographs out at review.
Nobody should be booking this two weeks before a wedding.
The complications that matter here
Not many, but they're specific.
Paradoxical bulging. A visible protrusion on clenching, usually anterior, appearing weeks after treatment. It happens when part of the muscle is weakened and the untreated portion compensates. Usually manageable, usually related to placement, and much less likely if you covered the box properly rather than clustering points centrally.
Asymmetric smile. Almost always a placement problem, from injecting too high or too superficially. Resolves with time. Doesn't feel like it resolves quickly when it's on your patient's face.
Chewing fatigue. Common, mild, self-limiting. Warn about it.
Hollowing. In thin patients with little subcutaneous fat, aggressive or repeated masseter reduction can leave the lower face looking gaunt rather than sculpted. Judgement call at selection.
Loss of posterior support in older patients. This is the one experienced injectors get careful about. In a patient already showing jowling and skin laxity, reducing the muscle bulk that's providing some support underneath can make the sagging read worse, not better. Age and skin quality belong in the selection criteria, not just muscle size.
